Fundraising Fox

Adrenomed AG

Hennigsdorf, DE · Founded 2009 · 3 known investors

AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.

BiotechHealthtechMedical Devices

Founders & leadership

Adrenomed AG was founded in 2009 by Gerald Moeller.

GMGerald Moeller
Gerald MoellerinCo-founder and former CEO of AdrenoMed; Supervisory Board member
RJRichard Jones
Richard JonesinChief Executive Officer (CEO)
DG
David GermonpréinChief Financial Officer (CFO)

Investors · 3

Brandenburg KapitalPotsdam · $108K – $5.4M
Catalyze CapitalAmsterdam · $1.6M
VU Venture PartnersSan Francisco · $200K – $1M

In the news

Adrenomed AG | AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiativewebdisclosure.com · May 2026BioCentury - Adrenomed raises €24M series Dbiocentury.com · Nov 2018

Frequently asked questions

What does Adrenomed AG do?
AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.
Who founded Adrenomed AG?
Adrenomed AG was founded by Gerald Moeller in 2009.
Who are Adrenomed AG's investors?
Adrenomed AG's investors include Brandenburg Kapital, Catalyze Capital, VU Venture Partners.
Where is Adrenomed AG headquartered?
Adrenomed AG is headquartered in Hennigsdorf, DE.